Tonix updates development plans for Lyme disease prevention antibody
Tweet Send to a Friend
Tonix Pharmaceuticals Holding Corp. (NASDAQ: TNXP) announced program updates for TNX-4800, a long-acting monoclonal antibody designed to prevent Lyme disease ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


